Gilead Sciences IncNASDAQ:GILD
- LAST PRICE65.6650
- TODAY'S CHANGE (%)0.3950 (0.6052%)
- Bid / Lots65.6600/ 2
- Ask / Lots65.6800/ 5
- Open / Previous Close65.5000 / 65.2700
- Day Range
- 52 Week Range
- Volume5,423,287
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GILD |
|---|---|---|
| 09:32 ET | 266064 | 65.295 |
| 09:34 ET | 348814 | 65.9436 |
| 09:36 ET | 370393 | 65.87 |
| 09:38 ET | 96052 | 65.8814 |
| 09:39 ET | 74674 | 65.6141 |
| 09:41 ET | 80283 | 65.4 |
| 09:43 ET | 90719 | 65.86 |
| 09:45 ET | 59146 | 65.59 |
| 09:48 ET | 85709 | 65.4 |
| 09:50 ET | 61989 | 65.28 |
| 09:52 ET | 39851 | 65.0762 |
| 09:54 ET | 56449 | 64.98 |
| 09:56 ET | 36222 | 64.83 |
| 09:57 ET | 41043 | 64.74 |
| 09:59 ET | 42057 | 64.71 |
| 10:01 ET | 65139 | 65.02 |
| 10:03 ET | 67640 | 65.04 |
| 10:06 ET | 54711 | 64.8 |
| 10:08 ET | 60975 | 65.145 |
| 10:10 ET | 109222 | 65 |
| 10:12 ET | 70732 | 65.31 |
| 10:14 ET | 47197 | 65.495 |
| 10:15 ET | 45702 | 65.62 |
| 10:17 ET | 59922 | 65.72 |
| 10:19 ET | 31755 | 65.655 |
| 10:21 ET | 68718 | 65.535 |
| 10:24 ET | 66800 | 65.47 |
| 10:26 ET | 45799 | 65.54 |
| 10:28 ET | 35361 | 65.49 |
| 10:30 ET | 24544 | 65.47 |
| 10:32 ET | 25069 | 65.515 |
| 10:33 ET | 41177 | 65.51 |
| 10:35 ET | 29220 | 65.425 |
| 10:37 ET | 24308 | 65.49 |
| 10:39 ET | 30423 | 65.42 |
| 10:42 ET | 44085 | 65.3225 |
| 10:44 ET | 24883 | 65.295 |
| 10:46 ET | 23827 | 65.27 |
| 10:48 ET | 105305 | 65.105 |
| 10:50 ET | 149972 | 65.25 |
| 10:51 ET | 27899 | 65.32 |
| 10:53 ET | 34858 | 65.315 |
| 10:55 ET | 62391 | 65.27 |
| 10:57 ET | 33795 | 65.25 |
| 11:00 ET | 21965 | 65.2 |
| 11:02 ET | 17524 | 65.37 |
| 11:04 ET | 32426 | 65.48 |
| 11:06 ET | 24550 | 65.455 |
| 11:08 ET | 30414 | 65.48 |
| 11:09 ET | 122982 | 65.5 |
| 11:11 ET | 67632 | 65.49 |
| 11:13 ET | 21163 | 65.485 |
| 11:15 ET | 27407 | 65.67 |
| 11:18 ET | 36998 | 65.56 |
| 11:20 ET | 31429 | 65.63 |
| 11:22 ET | 38179 | 65.7157 |
| 11:24 ET | 44763 | 65.69 |
| 11:26 ET | 31016 | 65.75 |
| 11:27 ET | 26953 | 65.75 |
| 11:29 ET | 82178 | 65.53 |
| 11:31 ET | 14618 | 65.6 |
| 11:33 ET | 107908 | 65.6 |
| 11:36 ET | 21791 | 65.575 |
| 11:38 ET | 15381 | 65.63 |
| 11:40 ET | 191705 | 65.78 |
| 11:42 ET | 40574 | 65.74 |
| 11:44 ET | 10791 | 65.75 |
| 11:45 ET | 14997 | 65.7472 |
| 11:47 ET | 16162 | 65.695 |
| 11:49 ET | 46421 | 65.75 |
| 11:51 ET | 22293 | 65.66 |
| 11:54 ET | 23133 | 65.5848 |
| 11:56 ET | 18134 | 65.675 |
| 11:58 ET | 16126 | 65.615 |
| 12:00 ET | 17039 | 65.685 |
| 12:02 ET | 3615 | 65.665 |
Today
Yesterday
DJ Gilead Sciences Posts Higher 1Q Sales, Swings to Loss on Charges, from 19 hours ago by Dow Jones
19 hours ago by Dow JonesDJ Gilead Beats Earnings Expectations After Rocky Quarter -- Barrons.com, from 20 hours ago by Dow Jones
20 hours ago by Dow JonesGilead Sciences Announces First Quarter 2024 Financial Results, from 20 hours ago by Dow Jones
20 hours ago by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Gilead Sciences Inc | 81.4B | 14.6x | +1.53% |
Amgen Inc | 144.5B | 21.6x | -0.22% |
HALEON PLC | 37.9B | 29.9x | --- |
Bristol-Myers Squibb Co | 90.6B | 11.7x | +4.90% |
Teva Pharmaceutical Industries Ltd | 14.8B | -27.3x | --- |
GSK plc | 85.1B | 13.7x | +6.39% |
Company Information
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.
Contact Information
- Headquarters
- 333 LAKESIDE DRFOSTER CITY, CA, United States 94404
- Phone
- 650-574-3000
- Fax
- 650-578-9264
Executives
- Chairman of the Board, Chief Executive Officer
- Daniel O'Day
- Chief Financial Officer
- Andrew Dickinson
- Executive Vice President - Corporate Affairs, General Counsel
- Deborah Telman
- Chief Commercial Officer
- Johanna Mercier
- Chief Medical Officer
- Merdad Parsey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $81.4B |
|---|---|
Revenue (TTM) | $27.1B |
Shares Outstanding | 1.2B |
Dividend Yield | 4.69% |
Annual Dividend Rate | 3.0800 USD |
Ex-Dividend Date | 03-14-24 |
Pay Date | 03-28-24 |
Beta | 0.23 |
EPS | $4.50 |
Book Value | $18.33 |
P/E Ratio | 14.6x |
Price/Sales (TTM) | 3.0 |
Price/Cash Flow (TTM) | 9.8x |
Operating Margin | 28.05% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
